In the high-stakes world of pharmaceutical development, the path from a lab bench to an FDA approval is notoriously fraught with failure. However, a silent crisis exists that has little to do with scientific failure and everything to do with corporate strategy: the "shelving" of promising drug candidates. According to Annette Bakker, CEO of the Children’s Tumor Foundation (CTF), there are currently more than 5,000 potential rare disease treatments gathering dust on the shelves of major pharmaceutical companies.
These aren’t necessarily failed experiments. In many cases, these molecules represent years of rigorous research, millions of dollars in investment, and verified preclinical or even Phase 1 clinical data. They are abandoned not because they lack efficacy or safety, but because they no longer align with a company’s commercial portfolio or because a corporate merger rendered them "surplus." Now, the CTF is leading a mission to bridge this gap, transforming from a traditional research funder into a sophisticated drug discovery engine designed to rescue these orphans of the industry.
The Economics of Abandonment: Why Promising Drugs Go Dark
To understand the scope of the problem, one must look at the way modern "Big Pharma" operates. Large corporations frequently acquire smaller, agile biotech firms specifically to obtain a "crown jewel" asset—a lead drug candidate that shows massive market potential. Often, the acquisition brings with it a secondary pipeline of other compounds that the purchasing company deems less commercially viable.
"Pharma assets are often shelved for commercial reasons rather than for efficacy or safety concerns," explains Dr. Bakker. When a company decides to pivot its therapeutic focus or trim its budget, these "non-core" assets are shelved. Once a drug is written off as a financial loss, the internal momentum dies. In the worst-case scenarios, when a smaller biotech is folded entirely, the proprietary data associated with these assets becomes inaccessible, effectively burying years of scientific progress.
For the rare disease community, this is a tragedy of lost opportunity. A drug that might be a "market failure" for a multi-billion dollar company because it targets a small patient population could be a life-saving breakthrough for the thousands of patients suffering from a rare genetic condition.
A Proven Model: The Case of Gomekli
The CTF’s methodology is not just theoretical; it has already produced tangible, life-changing results. The foundation’s work in neurofibromatosis (NF)—a group of genetic conditions characterized by the growth of tumors on nerves—serves as a blueprint for this "rescue" model.
The CTF acted as a catalyst for the development of MEK inhibitors, the technology that underpins the only two FDA-approved treatments for NF. But the foundation’s most striking success story involved a collaboration with Pfizer. Dr. Bakker identified a shelved asset within Pfizer’s portfolio that held significant promise for NF patients. Through persistent negotiation and strategic vision, she convinced the company to license the asset to a spin-off venture, SpringWorks Therapeutics, which was established in 2017.
The result was the development of Gomekli, which received FDA approval just last year. The success was staggering: the venture was eventually acquired by Merck KGaA in a deal valued at $3.4 billion. This transaction highlights the immense latent value hidden within the portfolios of major pharma companies—value that is currently being ignored.
The Mechanics of the "Rescue Engine"
To scale this model, the CTF has established a robust infrastructure. The foundation operates as a centralized hub, creating a network of preclinical models that allow it to evaluate, test, and shepherd drugs through the development pipeline.
Preclinical and Clinical Synergy
When a pharmaceutical company releases a shelved asset to the CTF, the foundation doesn’t start from scratch. Because the drug has already undergone extensive toxicology and early-stage development, the CTF can bypass years of early-phase work. "We could win all those years of preclinical and toxicology and go into clinical almost immediately," says Bakker.
The Recruitment Advantage
One of the most daunting barriers in rare disease research is patient recruitment. When a disease affects only a few thousand people globally—as is the case with the specific plexiform tumors targeted by Gomekli—finding a sufficient cohort for a clinical trial is a logistical nightmare.
"Everything you do in drug discovery is ten times harder in rare disease," Bakker admits. However, because the CTF maintains a deeply embedded network of patients and clinicians, they possess an inherent advantage that corporate entities often lack. By acting as a liaison between the patient community and the trial sponsors, the foundation significantly reduces the time and cost required to fill clinical trials, making the economics of these niche drugs far more attractive.
Challenges to Scaling: The "Closed Door" Problem
Despite the clear successes, the CTF faces a persistent cultural barrier within the pharmaceutical industry. Scaling this model requires a willingness from big pharma to open their vaults and share data—a practice that runs counter to decades of competitive secrecy.
Dr. Bakker notes that while she has found individual "champions" inside companies—such as Freda Lewis-Hall and Lara Sullivan at Pfizer, who were instrumental in the Gomekli project—these individuals are the exception rather than the rule. "We are looking for these champions in other companies that are willing to work with us, but the pharma companies we are calling are not opening the door," she says.
The challenge is twofold:
- Risk Aversion: Legal departments within pharma companies are often wary of the liability associated with licensing out shelved assets, even if the assets have a clean safety profile.
- Data Siloing: The internal bureaucracy of massive corporations often makes it difficult to even identify who owns the rights to a specific compound, let alone negotiate a spin-out.
Implications for the Future of Drug Discovery
If the CTF’s model can be adopted more broadly, it could lead to a fundamental shift in how the industry approaches rare disease. The current system—a "winner-takes-all" approach to R&D—is leaving thousands of patients behind.
A New Paradigm for Nonprofits
The role of the nonprofit is evolving from a mere provider of grants to an active, commercial-grade participant in the drug discovery process. By de-risking the assets through their own preclinical hubs, organizations like the CTF make it safer and more efficient for pharmaceutical companies to participate in rare disease research.
Policy and Industry Responsibility
There is a growing conversation around whether pharmaceutical companies should be required to disclose or "unlock" shelved assets that have reached a certain stage of development. If a company has no intention of pursuing a drug, some argue that the intellectual property should be made available to nonprofits or academia to prevent the loss of public and private investment.
The Human Impact
Ultimately, the statistics—the 5,000 shelved drugs, the billions in potential market value—must be contextualized by the patients. For an individual living with a debilitating neurofibromatosis tumor, a "shelved asset" is not a business decision; it is a potential cure that is being denied.
The Children’s Tumor Foundation is proving that the barrier to entry for rare disease cures isn’t always a lack of science—it is a lack of institutional imagination. By building an ecosystem that prioritizes the efficient movement of molecules from shelves to clinics, the CTF is offering a roadmap for how the industry can stop wasting its own breakthroughs.
As Dr. Bakker and her team continue their advocacy, the hope is that more pharmaceutical leaders will recognize that the real value of an asset isn’t just in its balance sheet, but in its potential to change a life. The "rescue engine" is ready; now, it just needs the industry to open the door.
About the Author
